


### CANCER/ UG sem 2/SDG





HALLMARKS OF CANCER



## **Hallmarks of Cancer**

- Sustaining proliferative signaling,
- Evading growth suppressors
- · Resisting cell death
- Enabling replicative Immortality
- Inducing angiogenesis
- Activating invasion and metastasis
- Deregulating cellular energetics
- Evading immune destruction

#### Multistep Process of Carcinogenesis Procarcinogen Threshold mechanisms Metabolic activation Metabolic Genotoxic carcinogen inactivation DNA repair DNA damage Cell cycle arrest Proliferation Apoptosis **DNA mutations** Proliferation Multistep process of oncogene activation ---- Apoptosis and tumor suppressor inactivation Senescence Control by immune system Tumor From: Hengstler, Bogdanffy, Bolt and Oesch, Annu Rev Pharmacol Toxicol. 2003;43:485-520





Fig. 2 - Chemical carcinogenesis stages and the occurrences involved in each one.

#### Different Steps of Carcinogenesis

<u>Initiation:</u> Mutation in one or more cellular genes controlling key regulatory pathways of the cell (irreversible)—must be a heritable DNA alteration.


<u>Promotion:</u> selective growth enhancement induced in the initiated cell and its progeny by the continuous exposure to a promoting agent.

<u>Progression:</u> results from continuing evolution of unstable chromosomes; further mutations from genetic instability during promotion—results in further degrees of independence, invasiveness, metastasis, etc.




## ras proto-oncogene:


- mutations in the ras gene are found in about 30% of human cancers
- the product is the <u>Ras</u> <u>protein</u>
- the Ras protein is a G
   protein that relays a growth
   signal from a growth factor
   receptor on the plasma
   membrane to a cascade of
   protein kinases




# RAS, the most frequently mutated or activated oncogene in human cancer


- Three Ras isoforms: H-ras, K-ras, and N-ras
- Mutated in 20-25% of tumors (G12D) but over 90% in pancreatic cancer
- •Mutations also common in colorectal and NSCLC
- Ras switches between active and inactive conformations.
- Ras mutations inhibit Ras GTPase activity thus locking it permanently in the active state.







- Ras is a GTP-binding protein and is the most widely studied oncoprotein.
- To achieve its biological activity, it must undergo post-translation modification. Ras acts as a typical molecular switch.
- The GTP-bound Ras can activate several downstream effector pathways.
  Ras signaling regulates many important physiologic processes within a cell, such as cell cycle progression, survival, apoptosis, etc.
- Several studies have found mutation in Ras or its effectors in various types of tumors.
- Therefore, Ras or its downstream effectors can be attractive drug targets against various types of tumors in cancer therapeutics.






Figure 4: Four Categories of Ras Inhibition Strategies

